Are blood clots in patients with heart-assist pumps decreasing or on the rise in 2015?

December 3, 2015, Elsevier

More left ventricular assist devices (LVADs), a mechanical heart that helps pump blood, are now implanted annually than hearts transplanted in patients with advanced stages of heart failure. Evidence-based data indicate that LVADs have saved many lives, whether as a bridge to heart transplantation or as a permanent therapy for heart failure. However, starting in 2011 device failures due to clots forming inside these pumps (pump thrombosis) appeared to rise dramatically. There is some indication that these failures may now be declining, but data analysis and interpretation are complex. In the current issue of the Journal of Heart and Lung Transplantation several studies suggest that management of patients with LVADs may have to change.

There has been vigorous debate within the medical community because multiple explanations for increased LVAD thrombosis rates have been posited. Using data from the Interagency Registry of Mechanically Assisted Circulation Support (INTERMACS), which tracks the use of LVADs worldwide, researchers from multiple centers analyzed information about contemporary trends in pump thrombosis following the spike in such events noted in 2011.

"In Late November of 2013, the Journal of Heart and Lung Transplantation first developed a compendium of articles on the emerging issue of pump thrombosis, which has led to a vigorous debate and attention to changed practices. We now present updated analyses to assess the impact of this renewed attentiveness to the issue," explained Mandeep R. Mehra, MD, Editor-in-Chief.

Two independent analyses, from the same databases appear in in this issue, the first from James K. Kirklin, MD, and co-investigators at the University of Alabama at Birmingham, and the second from Nicholas G. Smedira, MD, and colleagues at the Cleveland Clinic. Using the same INTERMACS data but analyzing with different statistical models, Kirklin confirmed an increasing risk of thrombosis from 2011 through 2013 followed by an observed decrease in risk in the first half of 2014, while Smedira's analysis concluded that there was no fallloff in 2014.

Neal Jeffries, PhD, and co-investigators at the National Heart, Lung, and Blood Institute, Bethesda, Maryland, ask, "What is the truth behind the recent trends – are thrombosis rates increasing, decreasing, or remaining relatively unchanged?" Their analysis of the INTERMACS data for the HeartMate II concluded that thrombosis risk has increased through 2011-2013 but whether this risk has been reduced in 2014 is inconclusive.

John M. Stulak, MD, and associates at the Mechanical Circulatory Support Research Network (Mayo Clinic College of Medicine, Vanderbilt Heart and Vascular Institute, and the University of Michigan) report on a study of treatment options for patients with a pump thrombosis while using the HeartWare device. Their conclusion was that the incidence of pump thrombosis with this device, approved for bridge to transplantation, is also significantly elevated and that medical therapy using anti-clotting and clot-dissolving drugs is unsuccessful in half of the cases, while pump replacement was uniformly successful. They also caution that, "the ideal approach remains elusive and will always depend heavily on a combination of patient-related and device-related factors and the weighing of risks of benefits of each approach."

An editorial by Garrick C. Stewart, MD, MPH, Michael M. Givertz, MD, and Mandeep R. Mehra, MD, from Brigham and Women's Hospital and Harvard Medical School, Boston, MA, discusses the current state of LVAD thromboses and patient care. Dr. Mehra noted that "These reports present sobering data on the consequences of pump thrombosis and suggest several important clinical directions. This series of studies is an important referendum on the INTERMACS registry, now entering its second decade, and confirm the vital role for collecting real-world data in cardiac device therapy." Importantly, they provide practical tips on communicating this information to patients who are being considered for pump implantation, to weigh the pros and cons of different devices and expected outcomes.

"Is there a glimmer of hope in reducing risk of pump thrombosis with newer devices?" asked Stewart, Givertz, and Mehra. "Promising preliminary data have emerged about the next-generation magnetically levitated centrifugal flow HeartMate 3. Engineering progress along with a better understanding of hemocompatibility will undoubtedly help to reduce the problem of pump thrombosis and will allow the expansion of into broader groups of patients. Until then we must redouble our efforts to ensure that today's patients live longer and better with approved pump technology even as we look with hope to the future."

Explore further: Two lefts make it right: Cardiac experts find novel approach to treat heart failure

More information: AN UPDATE ON PUMP THROMBOSIS: 2015
Pump Thrombosis Redux
Garrick C. Stewart, MD, MPH, Michael M. Givertz, MD, and Mandeep R. Mehra, MD

What is the Truth Behind Pump Thrombosis in the HeartMate II Device?: An NHLBI Perspective Based on Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) Data
Neal Jeffries, PhD, Marissa A. Miller, DVM, MPH, Wendy C. Taddei‐Peters, PhD, Catherine Burke, MA, J. Timothy Baldwin, PhD, James B. Young, MD

Current Risks of HeartMate II Pump Thrombosis: Nonparametric Analysis of INTERMACS Data
Nicholas G. Smedira, MD, Eugene H. Blackstone, MD, John Ehrlinger, PhD, Lucy Thuita, MS, Christopher D. Pierce, PhD, Nader Moazami, MD, Randall C. Starling, MD MPH

Treatment of device thrombus in the HeartWare HVAD: Success and outcomes depend significantly on the initial treatment strategy
John M. Stulak, MD, Shannon M. Dunlay, MD, MS, Shashank Sharma, MS, Nicholas A. Haglund, MD, Mary Beth Davis, MS, Jennifer Cowger, MS, MD, Palak Shah, MD, MS, Faraz Masood, MD, Keith D. Aaronson, MD, MS, Francis D. Pagani, MD, PhD, and Simon Maltais, MD, PhD

Pump Thrombosis in the Thoratec HeartMate II Device: An Update Analysis of the INTERMACS Registry
James K. Kirklin, MD, David C. Naftel, PhD, Francis D. Pagani, MD, PhD, Robert L. Kormos, MD, Susan Myers, MPH, Michael A. Acker, MD, Joseph Rogers, MD, Mark S. Slaughter, MD, and Lynne W. Stevenson, MD

Related Stories

Two lefts make it right: Cardiac experts find novel approach to treat heart failure

October 20, 2015
A teenage girl faced with sudden rapid heart deterioration, a man in the prime years of his life suffering from debilitating heart failure and a former NFL athlete crippled by end-stage heart failure were all successfully ...

Successful implant of next-generation heart device marks Canadian first

November 10, 2014
A surgical team at the Peter Munk Cardiac Centre led by internationally-acclaimed cardiovascular surgeon, Dr. Vivek Rao, has successfully implanted a novel mechanical device, the HeartMate IIITM, into a patient with advanced ...

Heart study aims to identify at-risk patients after pump implant

September 24, 2013
Emory researchers are exploring the use of echocardiography, an established non-invasive method to view the heart without radiation, to help identify patients at risk for right ventricular heart failure after implantation ...

Study raises concerns over safety of implanted heart pump

November 27, 2013
(HealthDay)—An implanted heart pump for people with weakened hearts, called the HeartMate II, appears to be plagued by dangerous clotting problems, a new study finds.

New patient guidelines for heart devices

April 17, 2011
A series of new guidelines for cardiac specialists has been developed to determine when heart failure patients should receive a mechanical heart-pumping device.

FDA OKs HeartWare device for transplant patients

November 20, 2012
The Food and Drug Administration on Tuesday approved a new heart pump for patients with severe heart failure who are awaiting a heart transplant.

Recommended for you

Heart failure patients shouldn't stop meds even if condition improves: study

November 13, 2018
(HealthDay)—There's bad news for heart failure patients with dilated cardiomyopathy who'd like to stop taking their meds.

Bypass beats stents for diabetics with heart trouble: study

November 13, 2018
(HealthDay)—People with both diabetes and multiple clogged heart arteries live longer if they undergo bypass surgery rather than have their blood vessels reopened with stents, according to follow-up results from a landmark ...

Kawasaki disease: One disease, multiple triggers

November 12, 2018
Researchers at University of California San Diego School of Medicine, Scripps Institution of Oceanography, and international collaborators have evidence that Kawasaki Disease (KD) does not have a single cause. By studying ...

New treatment significantly reduces cardiovascular events when combined with statins

November 12, 2018
Statins are the most commonly used treatment for cardiovascular disease. Despite reducing certain risk factors, if triglyceride levels remain high with use of statins, there is still a significant risk for heart attack, stroke ...

Study: How vitamin D and fish oil affect risk of heart attack, stroke and cancer

November 12, 2018
For years, it's remained an open question: What effects do dietary supplements such as high doses of vitamin D or omega-3 fatty acids derived from fish oil have on the risk of diseases such as heart attack, stroke and cancer? ...

Diabetes drug might also ease heart failure risks

November 12, 2018
(HealthDay)—The diabetes drug Farxiga might do double-duty for patients, helping to ward off another killer, heart failure, new research shows.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.